MRD Partnership Could Matter For Bio Rad Laboratories Stock (BIO)

• Bio-Rad Laboratories recently featured at Bernstein’s 3rd Annual Healthcare Forum and is collaborating with Biodesix on Molecular Residual Disease monitoring that uses its Droplet Digital PCR technology to detect circulating tumor DNA at very low levels.
• The combination of progress in oncology MRD partnerships and renewed momentum in Clinical Diagnostics quality controls and blood typing highlights how Bio-Rad Laboratories is leaning on higher value testing niches while managing regional and currency headwinds.
• This analysis examines how Bio-Rad Laboratories' investment narrative is shaped by its ctDNA-focused MRD collaboration with Biodesix.

Scan for other healthcare and diagnostics stocks leaning into higher value testing niches by reviewing our hand picked 38 healthcare AI stocks aligned with trends Bio-Rad Laboratories is exposed to.

Bio-Rad Laboratories Investment Narrative Recap

To own Bio-Rad Laboratories, you need to be comfortable with a story that leans on higher value molecular tools and Clinical Diagnostics while accepting slower overall growth and some margin pressure. The near term swing factor is whether demand for quality controls, blood typing and process chromatography can offset softer instrument orders and weaker profitability.

The biggest risk still sits in policy and demand pressures in key regions, especially China, combined with lower net margins at 8.6% compared with 12.5% last year. The Bernstein forum appearance does not change that risk profile in a material way. It mostly reiterates where management is already focused.

The Biodesix update on Molecular Residual Disease programs is the announcement that ties closest to this setup. It puts Bio-Rad Laboratories' Droplet Digital PCR platforms at the center of a real world oncology use case, which matters for how investors think about assay pull through and consumables mix over time.

For catalysts, that MRD collaboration sits alongside existing QX Continuum and QX700 ddPCR launches as a test of execution. If partnerships like this convert into broader assay adoption and more recurring consumables revenue, they could gradually ease pressure from weak instrument demand and regional diagnostics headwinds, though they do not remove the core risks.

Bio-Rad Laboratories is currently modeled to grow revenue by 1.5% a year, reaching about $2.7 billion in sales and $224.0 million in earnings by 2029, compared with earnings of $222.4 million today. This implies an earnings increase of $1.6 million over that period.

Discover why Bio-Rad Laboratories' fair value indicates a 15% potential downside to its current price, which leaves little room for error.

Exploring Other Perspectives

For Bio-Rad Laboratories, the bearish analysts focus on pricing pressure as the key risk. They were assuming roughly flat revenue around $2.6b and counting on earnings rising to $232.1 million by 2029 on higher margins. That is a more cautious story than consensus, and the Bernstein forum plus the Biodesix MRD update may push some of those views to evolve. You can treat this spread in opinions as a reminder to compare several scenarios before deciding what feels reasonable for you.

Explore another Bio-Rad Laboratories fair value estimate, including one that suggests as much as 24% downside from the current price.

Form Your Own Verdict

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

• A great starting point for your Bio-Rad Laboratories research is our analysis highlighting 1 important warning sign that could impact your investment decision.
• See our latest analysis for Bio-Rad Laboratories. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Bio-Rad Laboratories' overall financial health at a glance.

Looking For More Ideas Beyond Bio-Rad Laboratories?

If the Bio-Rad Laboratories story has sharpened your thinking about risk, balance sheets and earnings quality, use that same lens across a wider watchlist with the Simply Wall St Screener.

• For investors who want quality at a discount, start by reviewing a focused set of 30 high quality undervalued stocks that combine fundamentals with more appealing entry prices.
• If capital preservation and resilience matter most to you, consider scanning a curated group of 30 resilient stocks with low risk scores that score well on stability and business strength.
• When you want to go beyond the usual tickers, broaden your watchlist with a 16 high quality undiscovered gems that have solid underlying metrics but attract less headline attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com